These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1722164)

  • 21. Overview of benign prostatic hypertrophy.
    Geller J
    Urology; 1989 Oct; 34(4 Suppl):57-63; discussion 87-96. PubMed ID: 2477935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The changing therapy of benign prostatic hyperplasia.
    Altwein JE
    Scand J Urol Nephrol Suppl; 1995; 168():1-6. PubMed ID: 7541546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can prostate epithelial content predict response to hormonal treatment of patients with benign prostatic hyperplasia?
    Eri LM; Svindland A
    Urology; 2000 Aug; 56(2):261-5. PubMed ID: 10925090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocrine treatment of benign prostatic hypertrophy: current concepts.
    Matzkin H; Braf Z
    Urology; 1991 Jan; 37(1):1-16. PubMed ID: 1702565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benign prostatic hyperplasia: an approach for the internist.
    Zippe CD
    Cleve Clin J Med; 1996; 63(4):226-36. PubMed ID: 8764693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serenoa repens (Permixon®) reduces intra- and postoperative complications of surgical treatments of benign prostatic hyperplasia.
    Anceschi R; Bisi M; Ghidini N; Ferrari G; Ferrari P
    Minerva Urol Nefrol; 2010 Sep; 62(3):219-23. PubMed ID: 20940691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New options in benign prostatic hyperplasia.
    Riehmann M; Bruskewitz R
    Hosp Pract (Off Ed); 1993 Feb; 28(2A):17-20, 23-4. PubMed ID: 7679393
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment options for benign prostatic hyperplasia in older men.
    Miano R; De Nunzio C; Asimakopoulos AD; Germani S; Tubaro A
    Med Sci Monit; 2008 Jul; 14(7):RA94-102. PubMed ID: 18591930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transurethral prostatectomy versus transurethral dilatation of the prostatic urethra for benign prostatic hyperplasia: a cost-utility analysis.
    Bisonni RS; Lawler FH; Holtgrave DR
    Fam Pract Res J; 1993 Mar; 13(1):25-36. PubMed ID: 7683449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical therapy for benign prostatic hyperplasia.
    Keetch DW; Andriole GL
    AJR Am J Roentgenol; 1995 Jan; 164(1):11-5; discussion 16-7. PubMed ID: 7527995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Surgical innovations in the treatment of benign prostatic hyperplasia: towards new standard treatments?].
    Cornu JN; Rouprêt M
    Prog Urol; 2007 Sep; 17(5 Suppl 1):1026-8. PubMed ID: 17969784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative randomized study on the efficaciousness of treatment of BOO due to BPH in patients with prostate up to 100 gr by endoscopic gyrus prostate resection versus open prostatectomy. Preliminary data.
    Giulianelli R; Brunori S; Gentile BC; Vincenti G; Nardoni S; Pisanti F; Shestani T; Mavilla L; Albanesi L; Attisani F; Mirabile G; Schettini M
    Arch Ital Urol Androl; 2011 Jun; 83(2):88-94. PubMed ID: 21826881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New conservative therapeutic approaches in benign prostatic hyperplasia].
    Schulze H; Berges R; Paschold K; Senge T
    Urologe A; 1992 Jan; 31(1):8-13. PubMed ID: 1372777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The current approach to the management of benign hypertrophy of the prostate].
    Abbou CC; Salomon L; Chopin D; Ravery V; Haillot O
    Ann Urol (Paris); 1996; 30(6-7):294-301; discussion 302-10. PubMed ID: 9092383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment options for benign prostatic hyperplasia.
    Portis AJ; Mador DR
    Can Fam Physician; 1997 Aug; 43():1395-404. PubMed ID: 9266125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].
    Fourcade RO; Picot MC; Gaudin AF; Texier N; Slama A
    Presse Med; 2007 May; 36(5 Pt 1):755-63. PubMed ID: 17329070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current therapies of benign prostatic hypertrophy. Can the new medical treatments replace endoscopic resection?].
    Pavone-Macaluso M
    Ann Urol (Paris); 1992; 26(3):140-4. PubMed ID: 1381162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical and nonmedical therapies for benign prostatic hypertrophy.
    Loughlin KR
    Geriatrics; 1991 Jun; 46(6):26-31, 34. PubMed ID: 1710196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Age-related androgen deficiency and benign prostatic hyperplasia: how to improve the rehabilitation of patients after transurethral surgery?].
    Martov AG; Ergakov DV
    Urologiia; 2016 Dec; (6):110-117. PubMed ID: 28248054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.